Email this article 
Antiparkinsonian effects of dicholine succinate (intranasal application of 0.2–5.0 mg/kg) was studied in the C57Bl/6 mice model of parkinsonism caused by a single i.p. injection of 25 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Dicholine succinate was found to be characterized by significant antiparkinsonian effects, as indicated by reduction of akinesia in the “open field” test horizontal locomotor activity (0.2, 1.0 and 5.0 mg/kg) and reduction of muscle rigidity assessed through the step length (1.0 and 5.0 mg/kg). However, dicholine succinate did not exhibit any effect on such major MPTP-induced parkinsonian symptoms as tremor, piloerection, latero- and retropulsion.
Antiparkinsonian effect of dicholine succinate on the model of MPTP-induced parkinsonism
- Authors: Sariev A.K.1, Rychikhin V.M.1, Pomytkin I.A.2, Voronina T.A.3
-
Affiliations:
- Research Center of Neurology, Russian Academy of Medical Sciences
- Biosignal, Ltd
- Research Institute of Pharmacology, Russian Academy of Medical Sciences
- Issue: Vol 5, No 4 (2011)
- Pages: 33-36
- Section: Original articles
- Submitted: 03.02.2017
- Published: 13.02.2017
- URL: https://annaly-nevrologii.com/journal/pathID/article/view/290
- DOI: https://doi.org/10.17816/psaic290
- ID: 290
Cite item
Full Text
Abstract
About the authors
A. K. Sariev
Research Center of Neurology, Russian Academy of Medical Sciences
Email: platonova@neurology.ru
Russian Federation, Moscow
V. M. Rychikhin
Research Center of Neurology, Russian Academy of Medical Sciences
Email: platonova@neurology.ru
Russian Federation, Moscow
I. A. Pomytkin
Biosignal, Ltd
Email: platonova@neurology.ru
Russian Federation, Moscow
T. A. Voronina
Research Institute of Pharmacology, Russian Academy of Medical Sciences
Author for correspondence.
Email: platonova@neurology.ru
Russian Federation, Moscow
References
- Воронина Т.А., Вальдман Е.А., Неробкова Л.Н. Методические указания по изучению антипаркинсонической активности фармакологических веществ, Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М., 2005: 295–307.
- Gerlach M., Riederer P. Animal models of Parkinson’s sdisease: An empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 1996; 103: 987–1041.
- German D.C., Nelson E.L., Liang С.L. et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 1996; 5: 299–312.
- Schapira A.H.V. Progress in neuroprotection in Parkinson’s disease. Eur. J. Neurol. 2008; 15 (Suppl. 1): 5–13.
- Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson’s disease. J. Neural Transm. 2001; 108: 1263–1282.
- Storozheva Z.I., Proshin A.T., Sherstnev V.V. et al. Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. BMC Pharmacol. 2008; 8: 1.
- Storozhevykh T.P., Senilova Y.E., Persiyantseva N.A. et al. Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neurosci. 2007; 8: 84.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).